全文获取类型
收费全文 | 2445篇 |
免费 | 210篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 80篇 |
妇产科学 | 25篇 |
基础医学 | 343篇 |
口腔科学 | 23篇 |
临床医学 | 227篇 |
内科学 | 412篇 |
皮肤病学 | 213篇 |
神经病学 | 252篇 |
特种医学 | 107篇 |
外科学 | 326篇 |
综合类 | 64篇 |
一般理论 | 2篇 |
预防医学 | 172篇 |
眼科学 | 121篇 |
药学 | 170篇 |
中国医学 | 3篇 |
肿瘤学 | 116篇 |
出版年
2022年 | 14篇 |
2021年 | 59篇 |
2020年 | 16篇 |
2019年 | 42篇 |
2018年 | 57篇 |
2017年 | 34篇 |
2016年 | 43篇 |
2015年 | 53篇 |
2014年 | 79篇 |
2013年 | 82篇 |
2012年 | 126篇 |
2011年 | 129篇 |
2010年 | 74篇 |
2009年 | 79篇 |
2008年 | 105篇 |
2007年 | 125篇 |
2006年 | 132篇 |
2005年 | 111篇 |
2004年 | 106篇 |
2003年 | 82篇 |
2002年 | 84篇 |
2001年 | 82篇 |
2000年 | 71篇 |
1999年 | 60篇 |
1998年 | 40篇 |
1997年 | 35篇 |
1996年 | 31篇 |
1995年 | 22篇 |
1994年 | 32篇 |
1993年 | 21篇 |
1992年 | 43篇 |
1991年 | 58篇 |
1990年 | 39篇 |
1989年 | 44篇 |
1988年 | 46篇 |
1987年 | 33篇 |
1986年 | 33篇 |
1985年 | 30篇 |
1984年 | 27篇 |
1983年 | 20篇 |
1982年 | 23篇 |
1981年 | 14篇 |
1980年 | 21篇 |
1979年 | 34篇 |
1978年 | 20篇 |
1976年 | 16篇 |
1975年 | 18篇 |
1974年 | 20篇 |
1973年 | 21篇 |
1972年 | 17篇 |
排序方式: 共有2682条查询结果,搜索用时 15 毫秒
61.
62.
Objective. To determine whether and how pharmacy students used knowledge learned in the classroom during their introductory pharmacy practice experiences (IPPEs) in community and hospital settings.Design. To reinforce course concepts and make connections between coursework and practice, students documented examples of how knowledge from first-year courses was used in IPPEs.Assessment. Data submitted were categorized by classroom-based pharmacy course, including the frequency with which each course was cited. For community practice experiences, most student examples of knowledge application related to the self-care therapeutics course, pharmacy practice laboratory course, and dose form/compounding laboratory courses. Hospital IPPE examples were most frequently based on the pharmaceutical calculations course, physiology/pathophysiology course, medicinal chemistry course, and pharmacy practice laboratory course.Conclusion. All prior classroom-based pharmacy courses were cited by students as being useful during IPPEs, although some were more frequently cited than others. This activity provided useful programmatic assessment data. 相似文献
63.
64.
65.
66.
67.
Styles LA; Schalkwijk CG; Aarsman AJ; Vichinsky EP; Lubin BH; Kuypers FA 《Blood》1996,87(6):2573-2578
Acute chest syndrome (ACS) is associated with significant morbidity and is the leading cause of death in patients with sickle cell disease (SCD). Recent reports suggest that bone marrow fat embolism can be detected in many cases of severe ACS. Secretory phospholipase A2 (sPLA2) is an important inflammatory mediator and liberates free fatty acids, which are felt to be responsible for the acute lung injury of the fat embolism syndrome. We measured SPLA2 levels in 35 SCD patients during 20 admissions for ACS, 10 admissions for vaso-occlusive crisis, and during 12 clinic visits when patients were at the steady state. Eleven non-SCD patients with pneumonia were also evaluated. To determine if there was a relationship between sPLA2 and the severity of ACS we correlated SPLA2 levels with the clinical course of the patient. In comparison with normal controls (mean = 3.1 +/- 1.1 ng/mL), the non- SCD patients with pneumonia (mean = 68.6 +/- 82.9 ng/mL) and all three SCD patient groups had an elevation of SPLA2 (steady state mean = 10.0 +/- 8.4 ng/mL; vaso-occlusive crisis mean = 23.7 +/- 40.5 ng/mL; ACS mean = 336 +/- 209 ng/mL). In patients with ACS sPLA2 levels were 100- fold greater than normal control values, 35 times greater than values in SCD patients at baseline, and five times greater than non-SCD patients with pneumonia. The degree of SPLA2 elevation in ACS correlated with three different measures of clinical severity and, in patients followed sequentially, the rise in SPLA2 coincided with the onset of ACS. The dramatic elevation of SPLA2 in patients with ACS but not in patients with vaso-occlusive crisis or non-SCD patients with pneumonia and the correlation between levels of SPLA2 and clinical severity suggest a role for SPLA2 in the diagnosis and, perhaps, in the pathophysiology of patients with ACS. 相似文献
68.
CE Faggons C Mabedi CG Shores S Gopal 《Malawi medical journal : the journal of Medical Association of Malawi》2015,27(3):79-87
Aim
Review the literature from 1990 to 2013 to determine known anatomic sites, risk factors, treatments, and outcomes of head and neck squamous cell carcinoma (HNSCC) in sub-Saharan Africa.Methods
Using a systematic search strategy, literature pertaining to HNSCC in sub-Saharan Africa was reviewed and patient demographics, anatomic sites, histology, stage, treatment, and outcomes were abstracted. The contributions of human immunodeficiency virus (HIV), human papillomavirus (HPV) and behavioural risk factors to HNSCC in the region were assessed.Results
Of the 342 papers identified, 46 were utilized for review, including 8611 patients. In sub-Saharan Africa, the oropharyngeal/oral cavity was found to be the most common site, with 7750 cases (90% of all cases). Few papers distinguished oropharyngeal from oral cavity, making identification of possible HPV-associated oropharyngeal squamous cell carcinoma (SCC) difficult. SCC of the nasopharynx, nasal cavity, or paranasal sinuses was identified in 410 patients (4.8% of all cases). Laryngeal SCC was found in 385 patients (4.5% of all cases), and only 66 patients (0.8% of all cases) with hypopharyngeal SCC were identified. In 862 patients with data available, 43% used tobacco and 42% used alcohol, and reported use varied widely and was more common in laryngeal SCC than that of the oropharyngeal/oral cavity. Toombak and kola nut use was reported to be higher in patients with HNSCC. Several papers reported HIV-positive patients with HNSCC, but it was not possible to determine HNSCC prevalence in HIV-positive compared to negative patients. Reports of treatment and outcomes were rare.Conclusions
The oropharyngeal/oral cavity was by far the most commonly reported site of HNSCC reported in sub-Saharan Africa. The roles of risk factors in HNSCC incidence in sub-Saharan Africa were difficult to delineate from the available studies, but a majority of patients did not use tobacco and alcohol. 相似文献69.
70.
Following a 4-week placebo period, 19 patients (12 male, average age 62.3 years) with chronic stable angina pectoris and a positive exercise test were treated with the beta-adrenoceptor antagonists bopindolol at increasing doses of 0.5, 1 and 2 mg, each being given once daily for 4 weeks. For the final 4 weeks of the study, active treatment was replaced by placebo. Maximum tolerated exercise (bicycle ergometry, performed 24 h after drug administration) increased dose-dependently from 519 +/- 59 s (baseline) to 758 +/- 95 s with 2 mg (p less than 0.001) and fell again to 508 +/- 48 s (placebo). The frequency of anginal attacks also fell dose-dependently from an average of 5.4 per week (baseline) to 0.5 with 2 mg (p less than 0.001) and rose again to 5.1 per week when active treatment was stopped. 相似文献